Hydroxychloroquine and Chloroquine in Prophylaxis and Treatment of COVID-19

    October 2020 in “ Journal of Pharmacy And Bioallied Sciences ”
    P Ravi Shankar, Subish Palaian, Shabaz Mohiuddin Gulam
    TLDR Hydroxychloroquine and chloroquine are not recommended for COVID-19 treatment due to insufficient evidence and safety concerns.
    The document reviewed the use of hydroxychloroquine (HCQ) and chloroquine (CQ) for COVID-19 treatment and prophylaxis, highlighting the uncertainty and controversy surrounding their efficacy and safety. Despite some studies suggesting potential benefits, significant risks, particularly cardiac issues, were associated with these drugs. The US FDA cautioned against their use due to cardiovascular risks, leading to the withdrawal of emergency use authorization in June 2020. The Indian Council for Medical Research recommended HCQ for asymptomatic healthcare workers and household contacts of COVID-19 patients. However, the document concluded that there was insufficient evidence to recommend these drugs for COVID-19, with ongoing clinical trials needed for more definitive guidance.
    Discuss this study in the Community →